Lions Gate Faces another Loss in War with Icahn

May 9th, 2010
| More
Lions Gate Entertainment faces another setback in its battle with Carl Icahn as its attempt to reinstate a poison pill to thwart Icahn’s takeover attempt was denied by the British Columbia appeals court. The British Columbia Securities Commission annulled Lions Gate’s poison pill on April 26 after it was determined that the pill was implemented by management without the proper shareholder approval. The poison pill aimed to prevent Carl Icahn’s takeover bid of the Santa Monica film and television studio by allowing shareholders to buy stock at a discount in order to dilute Icahn’s ownership percentage.

Lions Gate will now put the poison pill to a shareholder vote on May 12.

Carl Icahn’s tender offer of $7 per share is set to expire on May 10. The dismissal of the appeal should bolster Icahn’s takeover attempt as many investors were reluctant to sell their shares if the poison pill were to be reinstated. Icahn’s offer was originally set to explode on April 30 but was extended until May 10.
See Source
For Detailed Investor Profiles on these Investors, click below:
Icahn Associates (Carl Icahn)
Related People: Alexander J. Denner; Brett Icahn; Carl Icahn; Keith A. Meister*
Related Entities: High River Limited Partnership; Icahn Partners; Icahn & Co Inc; Icahn Associates; Icahn Enterprises (formerly American Real Estate Partners); Icahn Fund Ltd; Icahn Partners LP
Related Article Tags: Shareholder Activists, Corporate Raiders and Proxy Battles

More Recent Headlines

Pershing Square’s Bill Ackman Proposes Public Database to Prevent Fraud

Carl Icahn Plans to Replace Genzyme’s CEO and Three Directors

April a Good Month for Hedge Fund Returns

Lawyers for Galleon’s Raj Rajaratnam Fighting Wiretaps

Deutsche Telekom Discussing Partnership with Harbinger Capital Partners

Asian Development Bank launches $9 Billion Plan for Solar Energy in Asia

Feds Charge SpongeTech CEO with Obstruction of Justice in Pump and Dump Stock Investigation

Caxton veteran’s Redux Research launches Matrix Redux hedge fund

Another Senior Management Departure at Citadel Investment Group

Regulatory Environment makes US more attractive to Hedge Funds than Europe